Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

RITONAVIR

All products: general benefit

Other products in the same Health Canada class (J05A, J05AE) — coverage varies; not interchangeable

  • Atazanavir (Reyataz): general benefit, Not a benefit
  • Darunavir (Prezista): general benefit, Not a benefit
  • Fosamprenavir (Telzir): general benefit
  • Nelfinavir (Viracept): general benefit
  • Nirmatrelvir + ritonavir (Paxlovid): limited Use 673, 674, 675
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit

48 more in the class list below

Norvir · DIN 02357593 · 100mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Norvir · DIN 02357593 Manufacturer: Abbott Laboratories Limited; listing date 2012-02-29 Health Canada: Marketed since 2014-04-30 · brand NORVIR · ATC J05AE03 RITONAVIR · form Tablet · route Oral · ingredients RITONAVIR 100 MG · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.1745 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84270 · Verify on the e-Formulary ↗ (DIN 02357593)

Source record
DIN 02357593: Norvir Raw flags: sec3=Y Item: 081800350; group id 108; item number 0190; lccId None; manufacturer id ABB Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $1.5660; ministry $1.1745 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02357593 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84270
Interchangeable products
Auro-Ritonavir · DIN 02523620 · $1.1745
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

DARUNAVIR

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 600mg, 800mg · Tab

FOSAMPRENAVIR CALCIUM

· 2 products · General benefit · strengths: 50mg/mL, 700mg · Oral Susp, Tab

NELFINAVIR MESYLATE

· 2 products · General benefit · strengths: 250mg, 625mg · Tab

NIRMATRELVIR & RITONAVIR

· 2 products · Limited Use, codes 673, 674, 675 · strengths: 150mg & 100mg · Tab-20 Pk, Tab-30 Pk

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hiv infection
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ZIDOVUDINE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS APO-ZIDOVUDINE (zidovudine) is indicated for the treatment of HIV infection in adults and adolescents aged 12 years and older and weighing > 30 kg when antiretroviral therapy is warranted. PM: https://pdf.hres.ca/dpd_pm/00073667.PDF; date NOV 23, 2023; DIN 01946323; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications NORVIR (ritonavir) is indicated in combination with other antiretroviral agents for the treatment of HIV infection when therapy is warranted. 1.1. Pediatrics Pediatrics (2 to 16 years of age): NORVIR concentrations obtained after 350 to 400 mg/m² twice daily in pediatric patients were comparable to those obtained in adults receiving 600 mg (approximately 330 mg/m²) twice daily (see 10.3. Pharmacokinetics). The safety and effectiveness of NORVIR in pediatric patients below the age of 2 years have not been established. 1.2. Geriatrics Geriatrics (> 65 years of age): Clinical studies of NORVIR did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects. In general, appropriate caution should be exercised in the administration and monitoring of NORVIR in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. https://pdf.hres.ca/dpd_pm/00085371.PDF PM date: 2026-07-14 Source product: NORVIR; DIN 02357593; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.